Download Files:

ML347

SKU HY-12274-10 mg Category Tags , ,

$66$660

Products Details

Product Description

– ML347 (LDN193719) is a highly selective ALK1/ALK2 inhibitor. ML347 has IC50 values of 46 and 32 nM against ALK1 and ALK2, respectively, >300-fold selective over ALK3. ML347 block the phosphorylation of Smad1/5 by TGF-β1[1][2].

Web ID

– HY-12274

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Cancer-Kinase/protease

Molecular Formula

– C22H16N4O

References

– [1]Zhang H, et al. Dual roles of TGF-β signaling in the regulation of dental epithelial cell proliferation. J Mol Histol. 2021 Feb;52(1):77-86. |[2]Engers DW, et al. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.

CAS Number

– 1062368-49-3

Molecular Weight

– 352.39

Compound Purity

– 99.89

SMILES

– COC1=CC=C(C2=CN3C(N=C2)=C(C4=C5C=CC=NC5=CC=C4)C=N3)C=C1

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– DMSO : 10 mg/mL (ultrasonic)

Target

– TGF-β Receptor

Isoform

– ALK1;ALK2;ALK3

Pathway

– TGF-beta/Smad

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.